PPARγ2Pro12Ala polymorphism and human health

PPAR Research

Volumn , Issue , 2009, Pages

  He, Weimin ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72449192922     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/849538     Document Type: Article

References (224)

1. D. J. Mangelsdorf, C. Thummel, M. Beato, et al., "The nuclear receptor superfamily: the second decade, " Cell, vol. 83, no. 6, pp. 835-839, 1995.
2. C. K. Glass and S. Ogawa, "Combinatorial roles of nuclear receptors in inflammation and immunity, " Nature Reviews Immunology, vol. 6, no. 1, pp. 44-55, 2006.
3. D. J. Mangelsdorf and R. M. Evans, "The RXR heterodimers and orphan receptors, " Cell, vol. 83, no. 6, pp. 841-850, 1995.
4. V. Perissi and M. G. Rosenfeld, "Controlling nuclear receptors: the circular logic of cofactor cycles, " Nature Reviews Molecular Cell Biology, vol. 6, no. 7, pp. 542-554, 2005.
5. L. Fajas, D. Auboeuf, E. Raspe, et al., "The organization, promoter analysis, and expression of the human PPARy gene, " The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779-18789, 1997.
6. M. E. Greene, B. Blumberg, O. W. McBride, et al., "Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping, " Gene Expression, vol. 4, no. 4-5, pp. 281-299, 1995.
7. O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli, "Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-a,-/3, and-y in the adult rat, " Endocrinology, vol. 137, no. 1, pp. 354-366, 1996.
8. S. A. Kliewer, B. M. Forman, B. Blumberg, et al., "Differential expression and activation of a family of murine peroxisome proliferator- activated receptors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355-7359, 1994.
9. B. M. Spiegelman, "PPAR-y: adipogenic regulator and thia-zolidinedione receptor, " Diabetes, vol. 47, no. 4, pp. 507-514, 1998.
10. Y. Barak, M. C. Nelson, E. S. Ong, et al., "PPARy is required for placental, cardiac, and adipose tissue development, " Molecular Cell, vol. 4, no. 4, pp. 585-595, 1999.
11. E. D. Rosen, P. Sarraf, A. E. Troy, et al., "PPARy is required for the differentiation of adipose tissue in vivo and in vitro, " Molecular Cell, vol. 4, no. 4, pp. 611-617, 1999.
12. P. Tontonoz, E. Hu, and B. M. Spiegelman, "Stimulation of adipogenesis in fibroblasts by PPARy2, a lipid-activated transcription factor, " Cell, vol. 79, no. 7, pp. 1147-1156, 1994.
13. N. Kubota, Y. Terauchi, H. Miki, et al., "PPARy mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance, " Molecular Cell, vol. 4, no. 4, pp. 597-609, 1999.
14. W. He, Y Barak, A. Hevener, et al., "Adipose-specific peroxisome proliferator-activated receptor y knockout causes insulin resistance in fat and liver but not in muscle, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15712-15717, 2003.
15. T. Imai, R. Takakuwa, S. Marchand, et al., "Peroxisome proliferator-activated receptor y is required in mature white and brown adipocytes for their survival in the mouse, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 13, pp. 4543-4547, 2004.
16. J. R. Jones, C. Barrick, K.-A. Kim, et al., "Deletion of PPARγ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6207-6212, 2005.
17. L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, "Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ, " Cell, vol. 93, no. 2, pp. 229-240, 1998.
18. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, "PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL, " Cell, vol. 93, no. 2, pp. 241-252, 1998.
19. A. Chawla, W. A. Boisvert, C.-H. Lee, et al., "A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis, " Molecular Cell, vol. 7, no. 1, pp. 161-171, 2001.
20. K. J. Moore, E. D. Rosen, M. L. Fitzgerald, et al., "The role of PPAR-γ in macrophage differentiation and cholesterol uptake, " Nature Medicine, vol. 7, no. 1, pp. 41-47, 2001.
21. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, "The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation, " Nature, vol. 391, no. 6662, pp. 79-82, 1998.
22. D. Vats, L. Mukundan, J. I. Odegaard, et al., "Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation, " Cell Metabolism, vol. 4, no. 1, pp. 13-24, 2006.
23. A. L. Hevener, J. M. Olefsky, D. Reichart, et al., "Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidine-diones, " The Journal of Clinical Investigation, vol. 117, no. 6, pp. 1658-1669, 2007.
24. J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth, C. R. Morel, V. Subramanian, and L. Mukundan, "Macrophage-specific PPARγ controls alternative activation and improves insulin resistance, " Nature, vol. 447, no. 7148, pp. 1116-1120, 2007.
25. A. L. Hevener, W. He, Y. Barak, et al., "Muscle-specific Pparg deletion causes insulin resistance, " Nature Medicine, vol. 9, no. 12, pp. 1491-1497, 2003.
26. A. W. Norris, L. Chen, S. J. Fisher, et al., "Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones, " The Journal of Clinical Investigation, vol. 112, no. 4, pp. 608-618, 2003.
27. O. Gavrilova, M. Haluzik, K. Matsusue, et al., "Liver peroxi-some proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass, " The Journal of Biological Chemistry, vol. 278, no. 36, pp. 34268-34276, 2003.
28. K. Matsusue, M. Haluzik, G. Lambert, et al., "Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes, " The Journal of Clinical Investigation, vol. 111, no. 5, pp. 737-747, 2003.
29. Y. Wan, L.-W. Chong, and R. M. Evans, "PPAR-γ regulates osteoclastogenesis in mice, " Nature Medicine, vol. 13, no. 12, pp. 1496-1503, 2007.
30. G. Ding, M. Fu, Q. Qin, et al., "Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage, " Cardiovascular Research, vol. 76, no. 2, pp. 269-279, 2007.
31. S. Z. Duan, C. Y. Ivashchenko, M. W. Russell, D. S. Milstone, and R. M. Mortensen, "Cardiomyocyte-specffic knockout and agonist of peroxisome proliferator-activated receptor-γ both induce cardiac hypertrophy in mice, " Circulation Research, vol. 97, no. 4, pp. 372-379, 2005.
32. C. J. Nicol, M. Adachi, T. E. Akiyama, and F. J. Gonzalez, "PPARγ in endothelial cells influences high fat diet-induced hypertension, " American Journal of Hypertension, vol. 18, no. 4, pp. 549-556, 2005.
33. R. M. Evans, G. D. Barish, and Y.-X. Wang, "PPARs and the complex journey to obesity, " Nature Medicine, vol. 10, no. 4, pp. 355-361, 2004.
34. C. R. Kahn, L. Chen, and S. E. Cohen, "Unraveling the mechanism of action of thiazolidinediones, " The Journal of Clinical Investigation, vol. 106, no. 11, pp. 1305-1307, 2000.
35. J. M. Olefsky, "Treatment of insulin resistance with peroxi-some proliferator-activated receptor γ agonists, " The Journal of Clinical Investigation, vol. 106, no. 4, pp. 467-472, 2000.
36. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ), " The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953-12956, 1995.
37. Y. Chung-Jen, B. A. Beamer, C. Negri, et al., "Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation, " Biochemical and Biophysical Research Communications, vol. 241, no. 2, pp. 270-274, 1997.
38. A. K. Agarwal and A. Garg, "A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy, " The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 1, pp. 408-411, 2002.
39. M. Agostini, M. Gurnell, D. B. Savage, et al., "Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor γ, " Endocrinology, vol. 145, no. 4, pp. 1527-1538, 2004.
40. M. Agostini, E. Schoenmakers, C. Mitchell, et al., "Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance, " Cell Metabolism, vol. 4, no. 4, pp. 303-311, 2006.
41. I. Barroso, M. Gurnell, V. E. F. Crowley, et al., "Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension, " Nature, vol. 402, no. 6764, pp. 880-883, 1999.
42. R. A. Hegele, H. Cao, C. Frankowski, S. T. Mathews, and T. Leff, "PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy, " Diabetes, vol. 51, no. 12, pp. 3586-3590, 2002.
43. M. Ristow, D. Müller-Wieland, A. Pfeiffer, W. Krone, and C. R. Kahn, "Obesity associated with a mutation in a genetic regulator of adipocyte differentiation, " The New England Journal of Medicine, vol. 339, no. 14, pp. 953-959, 1998.
44. D. B. Savage, M. Agostini, I. Barroso, et al., "Digenic inheritance of severe insulin resistance in a human pedigree, " Nature Genetics, vol. 31, no. 4, pp. 379-384, 2002.
45. D. B. Savage, G. D. Tan, C. L. Acerini, et al., "Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ, " Diabetes, vol. 52, no. 4, pp. 910-917, 2003.
46. J. P. Berg, "Pluripotent PPARγ polymorphisms, " European Journal of Endocrinology, vol. 140, no. 4, pp. 293-295, 1999.
47. M. Gurnell, "PPARγ and metabolism: insights from the study of human genetic variants, " Clinical Endocrinology, vol. 59, no. 3, pp. 267-277, 2003.
48. S. Heikkinen, J. Auwerx, and C. A. Argmann, "PPARgamma in human and mouse physiology, " Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 999-1013, 2007.
49. Y. Kagawa, Y. Yanagisawa, K. Hasegawa, et al., "Single nucleotide polymorphisms of thrifty genes for energy metabolism: evolutionary origins and prospects for intervention to prevent obesity-related diseases, " Biochemical and Biophysical Research Communications, vol. 295, no. 2, pp. 207-222, 2002.
50. A. Meirhaeghe and P. Amouyel, "Impact of genetic variation of PPARγ in humans, " Molecular Genetics and Metabolism, vol. 83, no. 1-2, pp. 93-102, 2004.
51. S. S. Deeb, L. Fajas, M. Nemoto, et al., "A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity, " Nature Genetics, vol. 20, no. 3, pp. 284-287, 1998.
52. J. Masugi, Y. Tamori, H. Mori, T. Koike, and M. Kasuga, "Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-γ 2 on thiazolidinedione-induced adipogenesis, " Biochemical and Biophysical Research Communications, vol. 268, no. 1, pp. 178-182, 2000.
53. A. Doney, B. Fischer, D. Frew, et al., "Haplotype analysis of the PPARγ Prol 12Ala and CI431T variants reveals opposing associations with body weight, " BMC Genetics, vol. 3, article 21, pp. 1-8, 2002.
54. M. Barbieri, M. R. Rizzo, M. Papa, et al., "Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors, " Experimental Gerontology, vol. 40, no. 7, pp. 599-604, 2005.
55. C. M. Damcott, S. P. Moffett, E. Feingold, et al., "Genetic variation in fatty acid-binding protein-4 and peroxi-some proliferator-activated receptor γ interactively influence insulin sensitivity and body composition in males, " Metabolism: Clinical and Experimental, vol. 53, no. 3, pp. 303-309, 2004.
56. E. L. Rosado, J. Bressan, M. F. Martins, P. R. Cecon, and J. A. Mart'inez, "Polymorphism in the PPARgamma2 and beta2-adrenergic genes and diet lipid effects on body composition, energy expenditure and eating behavior of obese women, " Appetite, vol. 49, no. 3, pp. 635-643, 2007.
57. L. B. Tankó, A. Siddiq, C. Lecoeur, et al., "ACDC/adiponectin and PPAR-γ gene polymorphisms: implications for features of obesity, " Obesity Research, vol. 13, no. 12, pp. 2113-2121, 2005.
58. R. Bouhaha, D. Meyre, H. A. Kamoun, et al., "Effect of ENPP1/PC-1-K121Q and PPARγ-Pro12Ala polymorphisms on the genetic susceptibility to T2D in the Tunisian population, " Diabetes Research and Clinical Practice, vol. 81, no. 3, pp. 278-283, 2008.
59. M. Fornage, D. R. Jacobs Jr., M. W. Steffes, M. D. Gross, M. S. Bray, and P. J. Schreiner, "Inverse effects of the PPARγ2 Pro12Ala polymorphism on measures of adiposity over 15 years in African Americans and whites: the CARDIA study, " Metabolism: Clinical and Experimental, vol. 54, no. 7, pp. 910-917, 2005.
60. Q. Wei, D. R. Jacobs Jr., P. J. Schreiner, D. S. Siscovick, M. W. Steffes, and M. Fornage, "Patterns of association between PPARγ genetic variation and indices of adiposity and insulin action in African-Americans and whites: the CARDIA Study, " Journal of Molecular Medicine, vol. 84, no. 11, pp. 955-965, 2006.
61. T. Østergård, J. Ek, Y. Hamid, et al., "Influence of the PPAR-γ2 Pro12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of type 2 diabetic subjects, " Hormone and Metabolic Research, vol. 37, no. 2, pp. 99-105, 2005.
62. E. Goyenechea, M. D. Parra, and J. A. Mart'inez, "Weight regain after slimming induced by an energy-restricted diet depends on interleukin-6 and peroxisome-proliferator-activated-receptor-γ2 gene polymorphisms, " British Journal of Nutrition, vol. 96, no. 5, pp. 965-972, 2006.
63. N. Vogels, E. C. Mariman, F. G. Bouwman, A. D. Kester, K. Diepvens, and M. S. Westerterp-Plantenga, "Relation of weight maintenance and dietary restraint to peroxisome proliferator-activated receptor γ2, glucocorticoid receptor, and ciliary neurotrophic factor polymorphisms, " The American Journal of Clinical Nutrition, vol. 82, no. 4, pp. 740-746, 2005.
64. K. B. Adamo, R. Dent, C. D. Langefeld, et al., "Peroxisome proliferator-activated receptor γ 2 and acyl-CoA synthetase 5 polymorphisms influence diet response, " Obesity, vol. 15, no. 5, pp. 1068-1075, 2007.
65. S. A. Cole, B. D. Mitchell, W.-C. Hsueh, et al., "The Pro12Ala variant of peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) is associated with measures of obesity in Mexican Americans, " International Journal of Obesity and Related Metabolic Disorders, vol. 24, no. 4, pp. 522-524, 2000.
66. J. L. González Sánchez, M. Serrano, C. Fernández Pérez, M. Laakso, and M. T. Martínez Larrad, "Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population, " European Journal of Endocrinology, vol. 147, no. 4, pp. 495-501, 2002.
67. M. C. Ochoa, A. Marti, C. Azcona, et al., "Gene-gene interaction between PPARγ2 and ADRβ3 increases obesity risk in children and adolescents, " International Journal of Obesity, vol. 28, supplement 3, pp. S37-S41, 2004.
68. A. Meirhaeghe, M. W. T. Tanck, L. Fajas, et al., "Study of a new PPARγ2 promoter polymorphism and haplotype analysis in a French population, " Molecular Genetics and Metabolism, vol. 85, no. 2, pp. 140-148, 2005.
69. E. Morini, V. Tassi, D. Capponi, et al., "Interaction between PPARγ2 variants and gender on the modulation of body weight, " Obesity, vol. 16, no. 6, pp. 1467-1470, 2008.
70. J. Robitaille, J.-P. Després, L. Pérusse, and M.-C. Vohl, "The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Québec Family Study, " Clinical Genetics, vol. 63, no. 2, pp. 109-116, 2003.
71. V. S. Mattevi, V. M. Zembrzuski, and M. H. Hutz, "Effects of a PPARG gene variant on obesity characteristics in Brazil, " Brazilian Journal of Medical and Biological Research, vol. 40, no. 7, pp. 927-932, 2007.
72. C. W. Danawati, M. Nagata, H. Moriyama, et al., "A possible association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ2 gene with obesity in native Javanese in Indonesia, " Diabetes/Metabolism Research and Reviews, vol. 21, no. 5, pp. 465-469, 2005.
73. L.-L. Li, X.-L. Ma, J.-X. Ran, et al., "Genetic polymorphism of peroxisome proliferator-activated receptor-γ2 Pro12Ala on ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects, " Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 2, pp. 187-191, 2008.
74. V. Lagou, R. A. Scott, Y. Manios, et al., "Impact of perox-isome proliferator-activated receptors γ and δ on adiposity in toddlers and preschoolers in the GENESIS study, " Obesity, vol. 16, no. 4, pp. 913-918, 2008.
75. B. A. Beamer, C.-J. Yen, R. E. Andersen, et al., "Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations, " Diabetes, vol. 47, no. 11, pp. 1806-1808, 1998.
76. R. Valve, K. Sivenius, R. Miettinen, et al., "Two polymorphisms in the peroxisome proliferator-activated receptor-γ gene are associated with severe overweight among obese women, " The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 10, pp. 3708-3712, 1999.
77. K. S. Kim, S. M. Choi, S. U. Shin, H. S. Yang, and Y. Yoon, "Effects of peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism on body fat distribution in female Korean subjects, " Metabolism: Clinical and Experimental, vol. 53, no. 12, pp. 1538-1543, 2004.
78. E. C. Tok, D. Ertunc, O. Bilgin, E. M. Erdal, M. Kaplanoglu, and S. Dilek, "PPAR-γ2 Pro12Ala polymorphism is associated with weight gain in women with gestational diabetes mellitus, " European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 129, no. 1, pp. 25-30, 2006.
79. B. J. Nicklas, E. F. C. van Rossum, D. M. Berman, A. S. Ryan, K. E. Dennis, and A. R. Shuldiner, "Genetic variation in the peroxisome proliferator-activated receptor-γ2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain, " Diabetes, vol. 50, no. 9, pp. 2172-2176, 2001.
80. D. Evans, W. A. Mann, J. de Heer, et al., "Variation in the gene for human peroxisome proliferator activated receptor γ (PPARγ) does not play a major role in the development of morbid obesity, " International Journal of Obesity, vol. 24, no. 5, pp. 647-651, 2000.
81. M. Ghoussaini, D. Meyre, S. Lobbens, et al., "Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population, " BMC Medical Genetics, vol. 6, article 11, pp. 1-8, 2005.
82. T. L. Nelson, T. E. Fingerlin, L. Moss, M. M. Barmada, R. E. Ferrell, and J. M. Norris, "The PPARγ Pro12Ala polymorphism is not associated with body mass index or waist circumference among hispanics from Colorado, " Annals of Nutrition and Metabolism, vol. 51, no. 3, pp. 252-257, 2007.
83. Y. Mori, H. Kim-Motoyama, T. Katakura, et al., "Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men, " Biochemical and Biophysical Research Communications, vol. 251, no. 1, pp. 195-198, 1998.
84. 12Ala mutation in peroxisome proliferator-activated receptor-γ2 in Korean diabetic and obese subjects, " The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 5, pp. 1801-1804, 2000.
85. K. Kim, S. Lee, and R. J. Valentine, "Association of Pro12Ala polymorphism in the peroxisome proliferative-activated receptor γ2 gene with obesity and hypertension in Korean women, " Journal of Nutritional Science and Vitaminology, vol. 53, no. 3, pp. 239-246, 2007.
86. A. Stefanski, L. Majkowska, A. Ciechanowicz, et al., "Lack of association between the Pro12Ala polymorphism in PPAR-γ2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes, " Archives of Medical Research, vol. 37, no. 6, pp. 736-743, 2006.
87. A. Tönjes, M. Scholz, M. Loeffler, and M. Stumvoll, "Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals, " Diabetes Care, vol. 29, no. 11, pp. 2489-2497, 2006.
88. J. Luan, P. O. Browne, A.-H. Harding, et al., "Evidence for gene-nutrient interaction at the PPARγ locus, " Diabetes, vol. 50, no. 3, pp. 686-689, 2001.
89. A. Memisoglu, F. B. Hu, S. E. Hankinson, et al., "Interaction between a peroxisome proliferator-activated receptor γ gene polymorphism and dietary fat intake in relation to body mass, " Human Molecular Genetics, vol. 12, no. 22, pp. 2923-2929, 2003.
90. P.-I. Lin, J. M. Vance, M. A. Pericak-Vance, and E. R. Martin, "No gene is an island: the flip-flop phenomenon, " American Journal of Human Genetics, vol. 80, no. 3, pp. 531-538, 2007.
91. T.-J. Chen, C.-Y. Ji, X.-Y. Zheng, and Y.-H. Hu, "Association of β3 adrenergic receptor and peroxisome proliferator-activated receptor gamma 2 polymorphisms with insulin sensitivity: a twin study, " Biomedical and Environmental Sciences, vol. 20, no. 2, pp. 99-105, 2007.
92. W.-C. Hsueh, S. A. Cole, A. R. Shuldiner, et al., "Interactions between variants in the β3-adrenergic receptor and perox-isome proliferator-activated receptor-γ2 genes and obesity, " Diabetes Care, vol. 24, no. 4, pp. 672-677, 2001.
93. 2): beta-cell function and insulin sensitivity, " Deutsche Medizinische Wochenschrift, vol. 126, no. 20, pp. 580-584, 2001.
94. U. Helwig, D. Rubin, J. Kiosz, et al., "The minor allele of the PPARγ2 Pro12Ala polymorphism is associated with lower postprandial TAG and insulin levels in non-obese healthy men, " British Journal of Nutrition, vol. 97, no. 5, pp. 847-854, 2007.
95. T. Kahara, T. Takamura, T. Hayakawa, et al., "PPARγ gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men, " Metabolism: Clinical and Experimental, vol. 52, no. 2, pp. 209-212, 2003.
96. N. Stefan, A. Fritsche, H. Häring, and M. Stumvoll, "Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene, " Diabetes, vol. 50, no. 5, pp. 1143-1148, 2001.
97. M. Vänttinen, P. Nuutila, J. Pihlajamäki, et al., "The effect of the Ala12 allele of the peroxisome proliferator-activated receptor-γ2 gene on skeletal muscle glucose uptake depends on obesity: a positron emission tomography study, " The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 7, pp. 4249-4254, 2005.
98. R. Buzzetti, A. Petrone, A. M. Caiazzo, et al., "PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity, " Pediatric Research, vol. 57, no. 1, pp. 138-140, 2005.
99. S. Scaglioni, E. Verduci, M. Salvioni, et al., "PPAR-γ2 Pro12Ala variant, insulin resistance and plasma long-chain polyunsaturated fatty acids in childhood obesity, " Pediatric Research, vol. 60, no. 4, pp. 485-489, 2006.
100. R. Buzzetti, A. Petrone, M. C. Ribaudo, et al., "The common PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity, " European Journal of Human Genetics, vol. 12, no. 12, pp. 1050-1054, 2004.
101. M. Koch, K. Rett, E. Maerker, et al., "The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects, " Diabetologia, vol. 42, no. 6, pp. 758-762, 1999.
102. V. Tavares, R. D. C. Hirata, A. C. Rodrigues, et al., "Association between Pro12Ala polymorphism of the PPAR-γ2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus, " Diabetes, Obesity and Metabolism, vol. 7, no. 5, pp. 605-611, 2005.
103. 12Ala perox-isome proliferator- activated receptor γ2 polymorphism on glucose response to exercise training in type 2 diabetes, " Diabetologia, vol. 48, no. 8, pp. 1503-1509, 2005.
104. E. S. Kang, S. Y. Park, H. J. Kim, et al., "Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes, " Clinical Pharmacology & Therapeutics, vol. 78, no. 2, pp. 202-208, 2005.
105. P. Poulsen, G. Andersen, M. Fenger, et al., "Impact of two common polymorphisms in the PPARγ gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both?" Diabetes, vol. 52, no. 1, pp. 194-198, 2003.
106. F. Soriguer, S. Morcillo, F. Cardona, et al., "Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid, " The Journal of Nutrition, vol. 136, no. 9, pp. 2325-2330, 2006.
107. A.-H. Harding, D. E. M. Williams, S. H. J. Hennings, J. Mitchell, and N. J. Wareham, "Is the association between dietary fat intake and insulin resistance modified by physical activity?" Metabolism: Clinical and Experimental, vol. 50, no. 10, pp. 1186-1192, 2001.
108. P. W. Franks, J. Luan, P. O. Browne, et al., "Does peroxisome proliferator-activated receptor γ genotype (Pro12ala) modify the association of physical activity and dietary fat with fasting insulin level?" Metabolism: Clinical and Experimental, vol. 53, no. 1, pp. 11-16, 2004.
109. 2 P12A and PPARα L162V polymorphisms on glucose and insulin homeostasis: the Québec Family Study, " Journal of Human Genetics, vol. 48, no. 12, pp. 614-621, 2003.
110. D. Altshuler, J. N. Hirschhorn, M. Klannemark, et al., "The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes, " Nature Genetics, vol. 26, no. 1, pp. 76-80, 2000.
111. M. Stumvoll, N. Stefan, A. Fritsche, et al., "Interaction effect between common polymorphisms in PPARγ 2 (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity, " Journal of Molecular Medicine, vol. 80, no. 1, pp. 33-38, 2002.
112. R. Baratta, R. Di Paola, D. Spampinato, et al., "Evidence for genetic epistasis in human insulin resistance: the combined effect of PC-1 (K121Q) and PPARγ2 (P12A) polymorphisms, " Journal of Molecular Medicine, vol. 81, no. 11, pp. 718-723, 2003.
113. A. Pizzuti, L. Frittitta, A. Argiolas, et al., "A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance, " Diabetes, vol. 48, no. 9, pp. 1881-1884, 1999.
114. K. Hara, T. Okada, K. Tobe, et al., "The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes, " Biochemical and Biophysical Research Communications, vol. 271, no. 1, pp. 212-216, 2000.
115. M. Horiki, H. Ikegami, T. Fujisawa, et al., "Association of Pro12Ala polymorphism of PPARγ gene with insulin resistance and related diseases, " Diabetes Research and Clinical Practice, vol. 66, supplement 1, pp. S63-S67, 2004.
116. 12 → Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes, " Diabetes, vol. 50, no. 4, pp. 891-894, 2001.
117. M. K. Moon, Y. M. Cho, H. S. Jung, et al., "Genetic polymorphisms in peroxisome proliferator-activated receptor γ are associated with type 2 diabetes mellitus and obesity in the Korean population, " Diabetic Medicine, vol. 22, no. 9, pp. 1161-1166, 2005.
118. R. Meshkani, M. Taghikhani, B. Larijani, et al., "Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPARγ-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population, " Clinical Chemistry and Laboratory Medicine, vol. 45, no. 4, pp. 477-482, 2007.
119. A. S. F. Doney, B. Fischer, J. E. Cecil, et al., "Association of the Pro12Ala and C1431T variants of PPARG and their hap-lotypes with susceptibility to type 2 diabetes, " Diabetologia, vol. 47, no. 3, pp. 555-558, 2004.
120. L. Frederiksen, K. Brødbæk, M. Fenger, et al., "Studies of the Pro12Ala polymorphism of the PPAR-γ gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome, " The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 8, pp. 3989-3992, 2002.
121. L. Andrulionytè, J. Zacharova, J.-L. Chiasson, and M. Laakso, "Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial, " Diabetologia, vol. 47, no. 12, pp. 2176-2184, 2004.
122. R. Jaziri, S. Lobbens, R. Aubert, et al., "The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the data from an epidemiological study on the insulin resistance syndrome (DESIR) study, " Diabetes, vol. 55, no. 4, pp. 1157-1162, 2006.
123. A. Memisoglu, F. B. Hu, S. E. Hankinson, et al., "Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARγ gene and type 2 diabetes, " Diabetes Care, vol. 26, no. 10, pp. 2915-2917, 2003.
124. V. Radha, K. S. Vimaleswaran, H. N. S. Babu, et al., "Role of genetic polymorphism peroxisome proliferator-activated receptor-γ2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: evidence for heterogeneity, " Diabetes Care, vol. 29, no. 5, pp. 1046-1051, 2006.
125. D. Evans, J. de Heer, C. Hagemann, et al., "Association between the P12A and c1431t polymorphisms in the per-oxisome proliferator activated receptor γ (PPARγ) gene and type 2 diabetes, " Experimental and Clinical Endocrinology and Diabetes, vol. 109, no. 3, pp. 151-154, 2001.
126. C. Herder, W. Rathmann, K. Strassburger, et al., "Variants of the PPARG, IGF2BP2, CDKAL1, HHEX, and TCF7L2 genes confer risk of type 2 diabetes independently of BMI in the German KORA studies, " Hormone and Metabolic Research, vol. 40, no. 10, pp. 722-726, 2008.
127. T. O. Kilpeläinen, T. A. Lakka, D. E. Laaksonen, et al., "SNPs in PPARG associate with type 2 diabetes and interact with physical activity, " Medicine and Science in Sports and Exercise, vol. 40, no. 1, pp. 25-33, 2008.
128. M. Fiorito, I. Torrente, S. De Cosmo, et al., "Interaction of DIO2 T92A and PPARγ2 P12A polymorphisms in the modulation of metabolic syndrome, " Obesity, vol. 15, no. 12, pp. 2889-2895, 2007.
129. S. R. de Rooij, R. C. Painter, D. I. W. Phillips, et al., "The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene on glucose/insulin metabolism interact with prenatal exposure to famine, " Diabetes Care, vol. 29, no. 5, pp. 1052-1057, 2006.
130. J. C. Florez, K. A. Jablonski, M. W. Sun, et al., "Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone, " The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 4, pp. 1502-1509, 2007.
131. E. Zeggini, J. R. C. Parkinson, S. Halford, et al., "Examining the relationships between the Pro12Ala variant in PPARG and type 2 diabetes-related traits in UK samples, " Diabetic Medicine, vol. 22, no. 12, pp. 1696-1700, 2005.
132. D. K. Sanghera, L. Ortega, S. Han, et al., "Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk, " BMC Medical Genetics, vol. 9, article 59, pp. 1-9, 2008.
133. J. P. B. Vieira-Filho, A. F. Reis, T. S. Kasamatsu, et al., "Influence of the polymorphisms Tpr64Arg in the β3-adrenergic receptor gene and Pro12Ala in the PPARγ2 gene on metabolic syndrome-related
134. S. M. Wakil, K. Al-Rubeaan, O. Alsmadi, et al., "The peroxi-some proliferator-activated receptor-γ2 P12A polymorphism and type 2 diabetes in an Arab population, " Diabetes Care, vol. 29, no. 1, pp. 171-172, 2006.
135. F. P. Mancini, O. Vaccaro, L. Sabatino, et al., "Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes, " Diabetes, vol. 48, no. 7, pp. 1466-1468, 1999.
136. K. Z. Bouassida, L. Chouchane, K. Jellouli, et al., "The perox-isome proliterator activated receptorγ2 (PPARγ2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients, " Diabetes and Metabolism, vol. 31, no. 2, pp. 119-123, 2005.
137. R. Badii, A. Bener, M. Zirie, et al., "Lack of association between the Pro12Ala polymorphism of the PPAR-γ2 gene and type 2 diabetes mellitus in the Qatari consanguineous population, " Acta Diabetologica, vol. 45, no. 1, pp. 15-21, 2008.
138. M. T. Malecki, J. Frey, T. Klupa, et al., "The Pro12Ala polymorphism of PPARγ2 gene and susceptibility to type 2 diabetes mellitus in a Polish population, " Diabetes Research and Clinical Practice, vol. 62, no. 2, pp. 105-111, 2003.
139. S. P. Moffett, E. Feingold, M. M. Barmada, et al., "The C161 → T polymorphism in peroxisome proliferator-activated receptor gamma, but not P12A, is associated with insulin resistance in Hispanic and non-Hispanic white women: evidence for another functional variant in perox-isome proliferator-activated receptor gamma, " Metabolism: Clinical and Experimental, vol. 54, no. 11, pp. 1552-1556, 2005.
140. O. Ludovico, F. Pellegrini, R. Di Paola, et al., "Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on type 2 diabetes risk, " Obesity, vol. 15, no. 5, pp. 1076-1081, 2007.
141. R. Scacchi, A. Pinto, O. Rickards, et al., "An analysis of peroxisome proliferator-activated receptor gamma (PPAR-γ2) Pro12Ala polymorphism distribution and prevalence of type 2 diabetes mellitus (T2DM) in world populations in relation to dietary habits, " Nutrition, Metabolism and Cardiovascular Diseases, vol. 17, no. 9, pp. 632-641, 2007.
142. R. E. Pisabarro, C. Sanguinetti, M. Stoll, and D. Pren-dez, "High incidence of type 2 diabetes in peroxisome proliferator-activated receptor γ2 Pro12Ala carriers exposed to a high chronic intake of trans fatty acids and saturated fatty acids, " Diabetes Care, vol. 27, no. 9, pp. 2251-2252, 2004.
143. J. G. Eriksson, "Gene polymorphisms, size at birth, and the development of hypertension and type 2 diabetes, " The Journal of Nutrition, vol. 137, no. 4, pp. 1063-1065, 2007.
144. F. Mousavinasab, T. Tähtinen, J. Jokelainen, et al., "Effect of the Pro12Ala polymorphism of the PPARγ2 gene on serum adiponectin changes, " Endocrine, vol. 27, no. 3, pp. 307-309, 2005.
145. W.-S. Yang, C. A. Hsiung, L.-T. Ho, et al., "Genetic epistasis of adiponectin and PPARγ2 genotypes in modulation of insulin sensitivity: a family-based association study, " Dia-betologia, vol. 46, no. 7, pp. 977-983, 2003.
146. Z. Lu, B. Dong, X. Mo, et al., "Pro12Ala polymorphism in PPAR γ 2 associated with essential hypertension in Chinese nonagenarians/ centenarians, " Experimental Gerontology, vol. 43, no. 12, pp. 1108-1113, 2008.
147. F. J. Rodŕiguez-Esparragón, J. C. Rodŕiguez- Pérez, A. Maćias-Reyes, and F. Alamo-Santana, "Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are associated with essential hypertension, " Journal of Hypertension, vol. 21, no. 9, pp. 1649-1655, 2003.
148. C. J. Ostgren, U. Lindblad, O. Melander, A. Melander, L. Groop, and L. Råstam, "Peroxisome proliferator-activated receptor-γPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project, " Journal of Hypertension, vol. 21, no. 9, pp. 1657-1662, 2003.
149. H. Ylihärsilä, J. G. Eriksson, T. Forsén, et al., "Interactions between peroxisome proliferator-activated receptor-γ2 polymorphisms and size at birth on blood pressure and the use of antihypertensive medication, " Journal of Hypertension, vol. 22, no. 7, pp. 1283-1287, 2004.
150. A. Stefański, L. Majkowska, A. Ciechanowicz, et al., "Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes, " Journal of Human Hypertension, vol. 20, no. 9, pp. 684-692, 2006.
151. I. Gouni-Berthold, E. Giannakidou, D. Muller-Wieland, et al., "Peroxisome proliferator-activated receptor-γ2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2, " Journal of Hypertension, vol. 23, no. 2, pp. 301-308, 2005.
152. M. M. Swarbrick, C. M. Chapman, B. M. McQuillan, J. Hung, P. L. Thompson, and J. P. Beilby, "A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-γ2 is associated with combined hyperlipidaemia in obesity, " European Journal of Endocrinology, vol. 144, no. 3, pp. 277-282, 2001.
153. E. Iwata, H. Matsuda, T. Fukuda, et al., "Mutations of the peroxisome proliferator-activated receptor γ (PPARγ) gene in a Japanese population: the Pro12Ala mutation in PPARγ 2 is associated with lower concentrations of serum total and non-HDL cholesterol, " Diabetologia, vol. 44, no. 10, pp. 1354-1355, 2001.
154. R. L. Pollex, M. Mamakeesick, B. Zinman, S. B. Harris, R. A. Hegele, and A. J. G. Hanley, "Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes, " Journal of Diabetes and Its Complications, vol. 21, no. 3, pp. 166-171, 2007.
155. S.-M. Brand-Herrmann, T. Kuznetsova, A. Wiechert, et al., "Alcohol intake modulates the genetic association between HDL cholesterol and the PPARγ2 Pro12Ala polymorphism, " Journal of Lipid Research, vol. 46, no. 5, pp. 913-919, 2005.
156. E. S. Tai, D. Corella, M. Deurenberg-Yap, et al., "Differential effects of the C1431T and Pro12Ala PPARγ gene variants on plasma lipids and diabetes risk in an Asian population, " Journal of Lipid Research, vol. 45, no. 4, pp. 674-685, 2004.
157. T. Hamada, K. Kotani, K. Tsuzaki, et al., "Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor γ2 gene with small dense low-density lipoprotein in the general population, " Metabolism: Clinical and Experimental, vol. 56, no. 10, pp. 1345-1349, 2007.
158. J. Eriksson, V. Lindi, M. Uusitupa, et al., "The effects of the Pro12Ala polymorphism of the PPARγ-2 gene on lipid metabolism interact with body size at birth, " Clinical Genetics, vol. 64, no. 4, pp. 366-370, 2003.
159. E. J. Rhee, C. H. Kwon, W. Y. Lee, et al., "No association of Pro12Ala polymorphism of PPAR-γ gene with coronary artery disease in Korean subjects, " Circulation Journal, vol. 71, no. 3, pp. 338-342, 2007.
160. M. H. Zafarmand, Y. T. van der Schouw, D. E. Grobbee, P. W. de Leeuw, and M. L. Bots, "Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses, " Vascular Health and Risk Management, vol. 4, no. 2, pp. 427-436, 2008.
161. K. Rittig, C. Thamer, F. Machicao, et al., "The Pro12Ala polymorphism in PPARG2 increases the effectiveness of primary prevention of cardiovascular disease by a lifestyle intervention, " Diabetologia, vol. 50, no. 6, pp. 1345-1347, 2007.
162. K. Z. Al-Shali, A. A. House, A. J. G. Hanley, et al., "Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis, " Stroke, vol. 35, no. 9, pp. 2036-2040, 2004.
163. E. Iwata, I. Yamamoto, T. Motomura, et al., "The association of Pro12Ala polymorphism in PPARγ2 with lower carotid artery IMT in Japanese, " Diabetes Research and Clinical Practice, vol. 62, no. 1, pp. 55-59, 2003.
164. A. S. F. Doney, B. Fischer, G. Leese, A. D. Morris, and C. N. A. Palmer, "Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 12, pp. 2403-2407, 2004.
165. L. Li, L.-X. Cheng, R. Nsenga, M.-A. He, and T.-C. Wu, "Association between Pro12Ala polymorphism of peroxi-some proliferator-activated receptor-gamma 2 and myocar-dial infarction in the Chinese han population, " Clinical Cardiology, vol. 29, no. 7, pp. 300-304, 2006.
166. T. Pischon, J. K. Pai, J. E. Manson, et al., "Peroxisome proliferator-activated receptor-γ2 P12A polymorphism and risk of coronary heart disease in US men and women, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 8, pp. 1654-1658, 2005.
167. E. A. Ruiz-Narváez, P. Kraft, and H. Campos, "Ala12 variant of the peroxisome proliferator-activated receptor-γ gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction, " The American Journal of Clinical Nutrition, vol. 86, no. 4, pp. 1238-1242, 2007.
168. C.-C. Szeto, K.-M. Chow, P. Y.-K. Poon, B. C.-H. Kwan, and P. K.-T. Li, "Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy, " American Journal of Nephrology, vol. 28, no. 5, pp. 715-722, 2008.
169. M. L. Caramori, L. H. Canani, L. A. Costa, and J. L. Gross, "The human peroxisome proliferator-activated receptor γ2 (PPARγ2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes, " Diabetes, vol. 52, no. 12, pp. 3010-3013, 2003.
170. S.-M. Herrmann, J. Ringel, J.-G. Wang, J. A. Staessen, and E. Brand, "Peroxisome proliferator-activated receptor-γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study, " Diabetes, vol. 51, no. 8, pp. 2653-2657, 2002.
171. M. T. Malecki, K. Cyganek, B. Mirkiewicz-Sieradzka, et al., "Alanine variant of the Pro12Ala polymorphism of the PPARγ gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes, " Diabetes Research and Clinical Practice, vol. 80, no. 1, pp. 139-145, 2008.
172. R. S. Legro, A. R. Kunselman, W. C. Dodson, and A. Dunaif, "Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women, " The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 1, pp. 165-169, 1999.
173. S. Korhonen, S. Heinonen, M. Hiltunen, et al., "Polymorphism in the peroxisome proliferator-activated receptor-γ gene in women with polycystic ovary syndrome, " Human Reproduction, vol. 18, no. 3, pp. 540-543, 2003.
174. M. Yilmaz, M. A. Ergün, A. Karakoç, E. Yurtçu, N. Çakir, and M. Arslan, "Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ gene in women with poly-cystic ovary syndrome, " Gynecological Endocrinology, vol. 22, no. 6, pp. 336-342, 2006.
175. S. Hahn, A. Fingerhut, U. Khomtsiv, et al., "The per-oxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome, " Clinical Endocrinology, vol. 62, no. 5, pp. 573-579, 2005.
176. 12Ala polymorphism in the PPARγ gene, " The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 2, pp. 772-775, 2002.
177. E. C. Tok, A. Aktas, D. Ertunc, E. M. Erdal, and S. Dilek, "Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of per-oxisome proliferator-activated receptor (PPAR)-γ2 Pro12Ala genotype, " Human Reproduction, vol. 20, no. 6, pp. 1590-1595, 2005.
178. M. Yilmaz, M. A. Ergün, A. Karakoç, et al., "Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ gene in first-degree relatives of subjects with polycystic ovary syndrome, " Gynecological Endocrinology, vol. 21, no. 4, pp. 206-210, 2005.
179. J. Schneider, J. Kreuzer, A. Hamann, P. P. Nawroth, and K. A. Dugi, "The proline 12 alanine substitution in the peroxisome proliferator- activated receptor-γ2 gene is associated with lower lipoprotein lipase activity in vivo, " Diabetes, vol. 51, no. 3, pp. 867-870, 2002.
180. J. Delarue and C. Magnan, "Free fatty acids and insulin resistance, " Current Opinion in Clinical Nutrition and Metabolic Care, vol. 10, no. 2, pp. 142-148, 2007.
181. G. D. Tan, M. J. Neville, E. Liverani, et al., "The in vivo effects of the Pro12Ala PPARγ2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank, " Diabetologia, vol. 49, no. 1, pp. 158-168, 2006.
182. 2?" Diabetologia, vol. 45, no. 1, pp. 152-153, 2002.
183. 2 gene is associated with increased antilipolytic insulin sensitivity, " Diabetes, vol. 50, no. 4, pp. 876-881, 2001.
184. I. Shimomura, R. E. Hammer, S. Ikemoto, M. S. Brown, and J. L. Goldstein, "Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy, " Nature, vol. 401, no. 6748, pp. 73-76, 1999.
185. T. Yamauchi, J. Kamon, Y. Minokoshi, et al., "Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, " Nature Medicine, vol. 8, no. 11, pp. 1288-1295, 2002.
186. I. Simón, J. Vendrell, C. Gutiérrez, et al., "Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma is associated with increased leptin levels in women with type-2 diabetes mellitus, " Hormone Research, vol. 58, no. 3, pp. 143-149, 2002.
187. N. Takata, T. Awata, K. Inukai, et al., "Pro12Ala substitution in peroxisome proliferator-activated receptorγ2 is associated with low adiponectin concentrations in young Japanese men, " Metabolism: Clinical and Experimental, vol. 53, no. 12, pp. 1548-1551, 2004.
188. 2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population, " Metabolism: Clinical and Experimental, vol. 51, no. 11, pp. 1407-1409, 2002.
189. F. Orio Jr., S. Palomba, T. Cascella, et al., "Lack of an association between peroxisome proliferator-activated receptor-γ gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome, " The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 10, pp. 5110-5115, 2004.
190. V. Radha, K. S. Vimaleswaran, S. Babu, et al., "Lack of association between serum adiponectin levels and the Pro12Ala polymorphism in Asian Indians, " Diabetic Medicine, vol. 24, no. 4, pp. 398-402, 2007.
191. S. Furukawa, T. Fujita, M. Shimabukuro, et al., "Increased oxidative stress in obesity and its impact on metabolic syndrome, " The Journal of Clinical Investigation, vol. 114, no. 12, pp. 1752-1761, 2004.
192. N. Houstis, E. D. Rosen, and E. S. Lander, "Reactive oxygen species have a causal role in multiple forms of insulin resistance, " Nature, vol. 440, no. 7086, pp. 944-948, 2006.
193. W. Luo, J. Cao, J. Li, and W. He, "Adipose tissue-specific PPARγ deficiency increases resistance to oxidative stress, " Experimental Gerontology, vol. 43, no. 3, pp. 154-163, 2008.
194. P. Tontonoz and B. M. Spiegelman, "Fat and beyond: the diverse biology of PPARγ, " Annual Review of Biochemistry, vol. 77, pp. 289-312, 2008.
195. Z. Gong, D. Xie, Z. Deng, et al., "The PPARγ Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas, " Carcinogenesis, vol. 26, no. 3, pp. 579-585, 2005.
196. M. A. Murtaugh, K. Ma, B. J. Caan, et al., "Interactions of peroxisome proliferator-activated receptor γ and diet in etiology of colorectal cancer, " Cancer Epidemiology Biomarkers & Prevention, vol. 14, no. 5, pp. 1224-1229, 2005.
197. G. Theodoropoulos, I. Papaconstantinou, E. Felekouras, et al., "Relation between common polymorphisms in genes related to inflammatory response and colarectal cancer, " World Journal of Gastroenterology, vol. 12, no. 31, pp. 5037-5043, 2006.
198. J. Jiang, V. Gajalakshmi, J. Wang, et al., "Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population, " Cancer Science, vol. 96, no. 8, pp. 507-512, 2005.
199. S.-Y. Liao, Z.-R. Zeng, W. K. Leung, et al., "Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese, " Alimentary Pharmacology & Therapeutics, vol. 23, no. 2, pp. 289-294, 2006.
200. K. N. Prasad, A. Saxena, U. C. Ghoshal, M. R. Bhagat, and N. Krishnani, "Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease, " Annals of Oncology, vol. 19, no. 7, pp. 1299-1303, 2008.
201. T. Tahara, T. Arisawa, T. Shibata, et al., "Influence of per-oxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese, " Digestive Diseases and Sciences, vol. 53, no. 3, pp. 614-621, 2008.
202. J. M. Zmuda, F. Modugno, J. L. Weissfeld, et al., "Peroxisome proliferator-activated receptor-γ polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction, " Oncology, vol. 70, no. 3, pp. 185-189, 2006.
203. D. Paltoo, K. Woodson, P. Taylor, D. Albanes, J. Virtamo, and J. Tangrea, "Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-γ) gene and risk of prostate cancer among men in a large cancer prevention study, " Cancer Letters, vol. 191, no. 1, pp. 67-74, 2003.
204. Y. Wang, M. L. McCullough, V. L. Stevens, et al., "Nested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer, " Anticancer Research, vol. 27, no. 1B, pp. 589-593, 2007.
205. 12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes, " Carcinogenesis, vol. 28, no. 2, pp. 427-434, 2007.
206. D. Leibovici, H. B. Grossman, C. P. Dinney, et al., "Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival, " Journal of Clinical Oncology, vol. 23, no. 24, pp. 5746-5756, 2005.
207. W. M. Smith, X.-P. Zhou, K. Kurose, et al., "Opposite association of two PPARG variants with cancer: overrep-resentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases, " Human Genetics, vol. 109, no. 2, pp. 146-151, 2001.
208. M. L. Slattery, C. Sweeney, M. Murtaugh, et al., "Associations between vitamin D, vitamin D receptor gene and the andro-gen receptor gene with colon and rectal cancer, " International Journal of Cancer, vol. 118, no. 12, pp. 3140-3146, 2006.
209. M. Barbieri, M. Bonafè, M. R. Rizzo, et al., "Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)γ-2 with longevity, " Experimental Gerontology, vol. 39, no. 7, pp. 1095-1100, 2004.
210. I. E. Camacho, L. Serneels, K. Spittaels, P. Merchiers, D. Dominguez, and B. De Strooper, "Peroxisome proliferator-activated receptor γ induces a clearance mechanism for the amyloid-β peptide, " The Journal of Neuroscience, vol. 24, no. 48, pp. 10908-10917, 2004.
211. C. d'Abramo, S. Massone, J.-M. Zingg, et al., "Role of peroxisome proliferator-activated receptor γ in amyloid precursor protein processing and amyloid β-mediated cell death, " Biochemical Journal, vol. 391, no. 3, pp. 693-698, 2005.
212. M. Sastre, I. Dewachter, S. Rossner, et al., "Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 2, pp. 443-448, 2006.
213. R. Scacchi, A. Pinto, G. Gambina, A. Rosano, and R. M. Corbo, "The peroxisome proliferator-activated receptor gamma (PPAR-γ2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians, " Brain Research, vol. 1139, no. 1, pp. 1-5, 2007.
214. G. Hamilton, P. Proitsi, L. Jehu, et al., "Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARγ as susceptibility loci, " American Journal of Medical Genetics Part B, vol. 144, no. 4, pp. 508-516, 2007.
215. A. M. Koivisto, S. Helisalmi, J. Pihlajamäki, et al., "Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset al.zheimer's disease in the Finnish population, " Dementia and Geriatric Cognitive Disorders, vol. 22, no. 5-6, pp. 449-453, 2006.
216. S. Sauder, H. Kölsch, D. Lütjohann, et al., "Influence of peroxisome proliferator-activated receptor γ gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients, " Journal of Neural Transmission, vol. 112, no. 10, pp. 1381-1389, 2005.
217. W. Johnson, S. E. Harris, J. M. Starr, L. J. Whalley, and I. J. Deary, "PPARG Pro12Ala genotype and risk of cognitive decline in elders? Maybe with diabetes, " Neuroscience Letters, vol. 434, no. 1, pp. 50-55, 2008.
218. N. A. West, M. N. Haan, and H. Morgenstern, "The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study, " Neurobiology of Aging. In press.
219. U. Fagiolo, A. Cossarizza, E. Scala, et al., "Increased cytokine production in mononuclear cells of healthy elderly people, " European Journal of Immunology, vol. 23, no. 9, pp. 2375-2378, 1993.
220. J. Myśliwska, E. Bryl, J. Foerster, and A. Myśliwski, "Increase of interleukin 6 and decrease of interleukin 2 production during the ageing process are influenced by the health status, " Mechanisms of Ageing and Development, vol. 100, no. 3, pp. 313-328, 1998.
221. P. Pregelj, "Involvement of cholesterol in the pathogenesis of Alzheimer's disease: role of statins, " Psychiatria Danubina, vol. 20, no. 2, pp. 162-167, 2008.
222. P. C. Reid, Y. Urano, T. Kodama, and T. Hamakubo, "Alzheimer's disease: cholesterol, membrane rafts, iso-prenoids and statins, " Journal of Cellular and Molecular Medicine, vol. 11, no. 3, pp. 383-392, 2007.
223. C. S. Carlson, M. A. Eberle, M. J. Rieder, Q. Yi, L. Kruglyak, and D. A. Nickerson, "Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium, " The American Journal of Human Genetics, vol. 74, no. 1, pp. 106-120, 2004.
224. D. C. Crawford, C. S. Carlson, M. J. Rieder, et al., "Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations, " The American Journal of Human Genetics, vol. 74, no. 4, pp. 610-622, 2004.